|
2024
|
Invention
|
Method of treating disease or disorder using compositions comprising pharmaceutically acceptable ... |
|
|
Invention
|
Compositions comprising therapeutic proteins or peptides, and uses thereof.
Provided herein are ... |
|
|
Invention
|
Long acting peptide tyrosine tyrosine (pyy) analogs and methods of use.
This invention relates t... |
|
|
Invention
|
Long acting glucagon like polypeptide-1 (glp-1) receptor agonists and methods of use.
This inven... |
|
|
G/S
|
Pharmaceutical, medical therapeutics and medical preparations for the treatment of metabolic diso... |
|
|
Invention
|
Human amylin analog polypeptides and methods of use.
This invention relates to isolated polypept... |
|
|
Invention
|
Implant placement and removal systems.
Devices, methods, and systems are provided for placing an... |
|
|
Invention
|
Compositions comprising pharmaceutically acceptable salts of glucagon-like peptide-1 analogs and ... |
|
|
Invention
|
Compositions comprising pharmaceutically acceptable salts of amylin analogs and uses thereof. Pro... |
|
2023
|
Invention
|
Ionic liquid formulations for treating inflammatory and autoimmune diseases.
Disclosed herein ar... |
|
|
Invention
|
Glucagon-receptor selective polypeptides and methods of use thereof.
This invention relates to i... |
|
|
Invention
|
Long acting peptide tyrosine tyrosine (pyy) analogs and methods of use. 1/2), and improved solubi... |
|
|
Invention
|
Methods comprising continuous administration of a glp-1 receptor agonist and co-administration of... |
|
|
Invention
|
Ionic liquid formulations for treating diabetes.
Disclosed herein are ionic liquids and deep eut... |
|
2021
|
Invention
|
Long acting glucagon like polypeptide-1 (glp-1) receptor agonists and methods of use. 1/2), and i... |
|
|
Invention
|
Glucagon-receptor selective polypeptides and methods of use thereof. This invention relates to is... |
|
|
Invention
|
Use of human amylin analog polypeptides for providing superior glycemic control to type 1 diabeti... |
|
|
Invention
|
Long acting glucagon receptor selective peptides and methods of use.
This invention relates to i... |
|
2020
|
Invention
|
Rapid establishment and/or termination of substantial steady-state drug delivery. The present inv... |
|
2019
|
Invention
|
Human amylin analog polypeptides and methods of use. 1/2) and improved solubility and thermal sta... |
